Iloeje Uchenna H, Yang Hwai-I, Jen Chin-Lan, Su Jun, Wang Li-Yu, You San-Lin, Chen Chien-Jen
Global Epidemiology and Outcomes Research, Pharmaceutical Research Institute, Bristol-Myers Squibb Company Wallington, Connecticut, USA.
Clin Gastroenterol Hepatol. 2007 Aug;5(8):921-31. doi: 10.1016/j.cgh.2007.06.015.
BACKGROUND & AIMS: The study objective was to determine the risk of all-cause and cause-specific mortality as well as to examine the predictors of mortality in chronic hepatitis B infection.
We performed a prospective cohort study of 23,820 persons (age, 30-65 y) recruited between 1991 and 1992 and followed up through 2004 from 7 townships in Taiwan. The main outcomes were all-cause and liver-related mortality rates. Mortality analyses used time-to-events methods, and survival curves were derived by the Kaplan-Meier method. Cox proportional hazard models were used to estimate multivariable-adjusted hazard ratios.
There were 1814 deaths during a mean follow-up period of 12.5 years (282,323.7 person-years of follow-up evaluation). Persons positive for hepatitis B surface antigen (HBsAg) had significantly (P < .01) higher adjusted hazard ratios for all causes of mortality (1.7; 95% confidence interval [CI], 1.5-1.9), liver cancer mortality (22.4; 95% CI, 15.2-32.9), and chronic liver disease and cirrhosis mortality (5.4; 95% CI, 3.5-8.4). When compared with HBsAg-negative persons, hepatitis B virus (HBV)-infected persons with HBV DNA levels less than 10(4) had a high risk of hepatocellular carcinoma mortality (4.4; 95% CI, 2.4-8.2). In HBsAg-positive persons, the mortality rate increased with cohort entry serum HBV DNA level. Liver cancer mortality ranged from 72.8 per 100,000 person-years for subjects with HBV DNA levels less than 300 copies/mL to 815.6 per 100,000 person-years for those with HBV DNA levels of 1 million copies/mL or greater. Chronic liver disease and cirrhosis deaths ranged from 9.1 to 267.4 per 100,000 person-years.
Chronic HBV infection is associated with significant preventable excess mortality risk. This mortality risk is correlated strongly with the level of viral replication among other factors.
本研究的目的是确定慢性乙型肝炎感染患者全因死亡率和特定病因死亡率的风险,并探讨死亡率的预测因素。
我们对1991年至1992年间招募的23820名年龄在30 - 65岁之间的台湾7个乡镇居民进行了前瞻性队列研究,并随访至2004年。主要结局为全因死亡率和肝脏相关死亡率。死亡率分析采用事件发生时间方法,生存曲线通过Kaplan-Meier法得出。Cox比例风险模型用于估计多变量调整后的风险比。
在平均12.5年的随访期(282323.7人年的随访评估)内,共有1814人死亡。乙肝表面抗原(HBsAg)阳性者全因死亡率(调整后风险比为1.7;95%置信区间[CI],1.5 - 1.9)、肝癌死亡率(22.4;95% CI,15.2 - 32.9)以及慢性肝病和肝硬化死亡率(5.4;95% CI,3.5 - 8.4)的调整后风险比显著更高(P < 0.01)。与HBsAg阴性者相比,乙肝病毒(HBV)DNA水平低于10⁴的HBV感染者肝细胞癌死亡率风险较高(4.4;95% CI,2.4 - 8.2)。在HBsAg阳性者中,队列进入时血清HBV DNA水平越高,死亡率越高。肝癌死亡率从HBV DNA水平低于300拷贝/mL的受试者的每10万人年72.8例到HBV DNA水平为100万拷贝/mL或更高者的每10万人年815.6例不等。慢性肝病和肝硬化死亡率从每10万人年9.1例到267.4例不等。
慢性HBV感染与显著的可预防的额外死亡风险相关。这种死亡风险与病毒复制水平等其他因素密切相关。